Is BTMD or ABEO more profitable?

biote has a net margin of 8.29% compared to Abeona Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Abeona Therapeutics N/A -53.98% -38.52%

Which has better valuation and earnings, BTMD or UPB?

biote has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.41 $27.05M $0.44 4.77 Upstream Bio $2.85M 121.54 -$143.44M -$2.91 N/A

Is BTMD or UPB more profitable?

biote has a net margin of 8.29% compared to Upstream Bio's net margin of -4,718.96%. biote's return on equity of -25.72% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Upstream Bio -4,718.96% -43.82% -42.27%

Which has higher earnings & valuation, IRD or BTMD?

biote has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 21.57 -$49.59M -$1.33 N/A biote $192.22M 0.41 $27.05M $0.44 4.77

Is IRD or BTMD more profitable?

biote has a net margin of 8.29% compared to Opus Genetics' net margin of -892.36%. biote's return on equity of -25.72% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -892.36% -338.88% -191.21% biote 8.29% -25.72% 15.12%

Which has better valuation & earnings, BTMD or SLN?

biote has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.41 $27.05M $0.44 4.77 Silence Therapeutics $560K 772.71 -$88.61M -$1.59 N/A

Is BTMD or SLN more profitable?

biote has a net margin of 8.29% compared to Silence Therapeutics' net margin of -8,943.86%. biote's return on equity of -25.72% beat Silence Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Silence Therapeutics -8,943.86% -105.34% -52.79%

Which has preferable earnings and valuation, BTMD or AMRN?

biote has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.41 $27.05M $0.44 4.77 Amarin $213.65M 1.61 -$38.80M -$0.65 N/A

Is BTMD or AMRN more profitable?

biote has a net margin of 8.29% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat biote's return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Amarin -15.51% -2.99% -2.07%

biote (BTMD) Competitors

$2.10 -0.05 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.02 (+0.71%)

As of 07:48 PM Eastern

Compare

BTMD vs. ABEO, UPB, IRD, SLN, and AMRN

Should you buy biote stock or one of its competitors? MarketBeat compares biote with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with biote include Abeona Therapeutics (ABEO), Upstream Bio (UPB), Opus Genetics (IRD), Silence Therapeutics (SLN), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

How does biote compare to Abeona Therapeutics?

biote (NASDAQ:BTMD) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Abeona Therapeutics' average media sentiment score of 1.90 beat biote's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Abeona Therapeutics	Very Positive

biote has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

biote has a net margin of 8.29% compared to Abeona Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has lower revenue, but higher earnings than biote. biote is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.77
Abeona Therapeutics	$5.82M	55.03	$71.18M	$0.97	5.79

21.7% of biote shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

biote currently has a consensus target price of $2.75, suggesting a potential upside of 30.95%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 238.08%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

biote beats Abeona Therapeutics on 8 of the 15 factors compared between the two stocks.

How does biote compare to Upstream Bio?

biote (NASDAQ:BTMD) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

biote has a net margin of 8.29% compared to Upstream Bio's net margin of -4,718.96%. biote's return on equity of -25.72% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

biote has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

biote currently has a consensus price target of $2.75, indicating a potential upside of 30.95%. Upstream Bio has a consensus price target of $33.17, indicating a potential upside of 421.08%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

biote has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.77
Upstream Bio	$2.85M	121.54	-$143.44M	-$2.91	N/A

In the previous week, Upstream Bio had 3 more articles in the media than biote. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for biote. Upstream Bio's average media sentiment score of 0.52 beat biote's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Upstream Bio	Positive

Summary

biote beats Upstream Bio on 11 of the 16 factors compared between the two stocks.

How does biote compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Opus Genetics had 4 more articles in the media than biote. MarketBeat recorded 4 mentions for Opus Genetics and 0 mentions for biote. Opus Genetics' average media sentiment score of 0.17 beat biote's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Neutral
biote	Neutral

biote has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.57	-$49.59M	-$1.33	N/A
biote	$192.22M	0.41	$27.05M	$0.44	4.77

Opus Genetics presently has a consensus target price of $10.77, indicating a potential upside of 190.28%. biote has a consensus target price of $2.75, indicating a potential upside of 30.95%. Given Opus Genetics' stronger consensus rating and higher possible upside, research analysts clearly believe Opus Genetics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has a net margin of 8.29% compared to Opus Genetics' net margin of -892.36%. biote's return on equity of -25.72% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
biote	8.29%	-25.72%	15.12%

Opus Genetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, biote has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Summary

biote beats Opus Genetics on 9 of the 16 factors compared between the two stocks.

How does biote compare to Silence Therapeutics?

biote (NASDAQ:BTMD) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

21.7% of biote shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

biote has a net margin of 8.29% compared to Silence Therapeutics' net margin of -8,943.86%. biote's return on equity of -25.72% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

biote has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

biote presently has a consensus target price of $2.75, suggesting a potential upside of 30.95%. Silence Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 500.44%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

biote has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.77
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

In the previous week, Silence Therapeutics had 5 more articles in the media than biote. MarketBeat recorded 5 mentions for Silence Therapeutics and 0 mentions for biote. Silence Therapeutics' average media sentiment score of 1.37 beat biote's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Silence Therapeutics	Positive

Summary

biote beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.

How does biote compare to Amarin?

biote (NASDAQ:BTMD) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

biote has a net margin of 8.29% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Amarin	-15.51%	-2.99%	-2.07%

21.7% of biote shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

biote has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.77
Amarin	$213.65M	1.61	-$38.80M	-$0.65	N/A

biote has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Amarin has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

In the previous week, Amarin had 16 more articles in the media than biote. MarketBeat recorded 16 mentions for Amarin and 0 mentions for biote. Amarin's average media sentiment score of 0.56 beat biote's score of 0.00 indicating that Amarin is being referred to more favorably in the news media.

Company	Overall Sentiment
biote	Neutral
Amarin	Positive

biote presently has a consensus target price of $2.75, suggesting a potential upside of 30.95%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 26.95%. Given biote's stronger consensus rating and higher possible upside, equities research analysts plainly believe biote is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

biote beats Amarin on 10 of the 16 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTMD vs. The Competition

Export

Metric	biote	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$80.80M	$8.18B	$6.56B	$12.24B
Dividend Yield	N/A	2.59%	2.69%	5.82%
P/E Ratio	4.89	15.21	25.17	23.98
Price / Sales	0.41	5.89	553.76	120.62
Price / Cash	3.70	16.83	44.82	54.51
Price / Book	-1.50	3.29	10.76	6.41
Net Income	$27.05M	$226.25M	$3.56B	$337.14M
7 Day Performance	-7.49%	-0.96%	1.37%	-0.48%
1 Month Performance	5.53%	-2.77%	0.81%	0.49%
1 Year Performance	-47.37%	0.16%	30.53%	28.16%

biote Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTMD biote	4.2607 of 5 stars	$2.10 -2.3%	$2.75 +31.0%	-46.4%	$80.80M	$192.22M	4.89	194	High Trading Volume
ABEO Abeona Therapeutics	3.4431 of 5 stars	$5.70 +0.5%	$19.00 +233.4%	-1.5%	$324.79M	$5.82M	5.88	90
UPB Upstream Bio	2.088 of 5 stars	$5.91 -3.2%	$33.17 +461.6%	-41.0%	$321.41M	$2.85M	N/A	38	News Coverage
IRD Opus Genetics	2.8441 of 5 stars	$3.88 -0.9%	$10.67 +175.3%	+350.2%	$319.96M	$14.20M	N/A	14	Analyst Forecast
SLN Silence Therapeutics	3.2185 of 5 stars	$6.74 -3.7%	$55.00 +715.9%	+26.0%	$318.45M	$560K	N/A	100	News Coverage Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTMD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

biote (BTMD) Competitors

BTMD vs. ABEO, UPB, IRD, SLN, and AMRN

How does biote compare to Abeona Therapeutics?

Summary

How does biote compare to Upstream Bio?

Summary

How does biote compare to Opus Genetics?

Summary

How does biote compare to Silence Therapeutics?

Summary

How does biote compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

biote (BTMD) Competitors

BTMD vs. ABEO, UPB, IRD, SLN, and AMRN

How does biote compare to Abeona Therapeutics?

Does the media refer more to BTMD or ABEO?

Which has more risk & volatility, BTMD or ABEO?

Is BTMD or ABEO more profitable?

Which has better earnings & valuation, BTMD or ABEO?

Do institutionals & insiders hold more shares of BTMD or ABEO?

Do analysts prefer BTMD or ABEO?

Summary

How does biote compare to Upstream Bio?

Is BTMD or UPB more profitable?

Which has more risk & volatility, BTMD or UPB?

Do institutionals and insiders have more ownership in BTMD or UPB?

Do analysts rate BTMD or UPB?

Which has better valuation and earnings, BTMD or UPB?

Does the media refer more to BTMD or UPB?

Summary

How does biote compare to Opus Genetics?

Do insiders & institutionals have more ownership in IRD or BTMD?

Does the media favor IRD or BTMD?

Which has higher earnings & valuation, IRD or BTMD?

Do analysts recommend IRD or BTMD?

Is IRD or BTMD more profitable?

Which has more volatility and risk, IRD or BTMD?

Summary

How does biote compare to Silence Therapeutics?

Do insiders & institutionals hold more shares of BTMD or SLN?

Is BTMD or SLN more profitable?

Which has more risk and volatility, BTMD or SLN?

Do analysts recommend BTMD or SLN?

Which has better valuation & earnings, BTMD or SLN?

Does the media refer more to BTMD or SLN?

Summary

How does biote compare to Amarin?

Is BTMD or AMRN more profitable?

Do institutionals and insiders hold more shares of BTMD or AMRN?

Which has preferable earnings and valuation, BTMD or AMRN?

Which has more volatility & risk, BTMD or AMRN?

Does the media favor BTMD or AMRN?

Do analysts rate BTMD or AMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD vs. The Competition

biote Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools